TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Keymed Biosciences, Inc. ( (HK:2162) ) just unveiled an update.
Keymed Biosciences Inc. has announced its upcoming Annual General Meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for the directors to issue new shares, which could impact its market position by potentially increasing capital for future projects.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies. The company is known for its work in biopharmaceuticals, targeting various medical conditions with a strong emphasis on research and development.
YTD Price Performance: 36.73%
Average Trading Volume: 2,263,812
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.06B
See more data about 2162 stock on TipRanks’ Stock Analysis page.